



































































This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process which may lead to 




Management of Advanced Therapies in Parkinson’s Disease Patients in times of 
Humanitarian crisis: the COVID-19 experience 
 
Alfonso Fasano, MD, PhD,1,2,3 Angelo Antonini, MD,4 Regina Katzenschlager, MD,5  
Paul Krack, MD,6 Per Odin, MD,7 Andrew H Evans, MD,8 Thomas Foltynie, MD,9  
Jens Volkmann, MD,10 Marcelo Merello, MD, PhD11,12 
 
1Edmond J. Safra Program in Parkinson’s Disease and the Morton and Gloria Shulman Movement Disorders Centre, 
Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, Canada 
2Krembil Brain Institute, Toronto, Canada 
3The Center for Advancing Neurotechnological Innovation to Application (CRANIA), Toronto, ON, Canada 
4Department of Neuroscience, University of Padua, Italy 
5Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative 
Disorders, Donauspital, Vienna, Austria 
6Department of Neurology, Center for Parkinson’s Disease and Movement Disorders, Inselspital, Bern University 
Hospital, University of Bern, Switzerland 
7Division of Neurology, Dept of Clinical Sciences Lund, Lund University, Lund, Sweden 
8Department of Neurology, the Royal Melbourne Hospital, Victoria, Australia 9Department of Clinical & Movement 
Neurosciences, UCL Institute of Neurology, Queen Square, London, UK. WC1N 3BG 
10Neurologischen Klinik, Universitätsklinikum Würzburg, Würzburg, Germany 
11Movement Disorders Section Fleni. Buenos Aires, Argentina 




Supplementary material online: Tables 1 and 2 
Funding sources: none. 
Conflict of Interest: Alfonso Fasano received honoraria and research support from Abbvie, Abbott, Boston 
Scientific and Medtronic. Angelo Antonini received honoraria from AbbVie, Neuroderm and  research support 
from Chiesi Pharmaceuticals. Regina Katzenschlager has received honoraria from AbbVie, Britannia, Ever 
Pharma, Stada and research grants from Britannia and Stada. Paul Krack reports grants from Boston Scientific 
and Aleva, lecturing fees paid to employing institution from Boston Scientific. Per Odin has received honoraria 
and research support from AbbVie, Britannia, and Nordic Infucare. Andrew H Evans received honoraria from 
AbbVie, Britannia, Abbott. Tom Foltynie has received honoraria from Boston Scientific. Jens Volkmann reports 
grants and lecturing fees from Boston Scientific and advisory fees paid by Boston Scientific, Medtronic, and 
Newronika. Marcelo Merello reports grants and lecturing fees from St. Jude Medical/Abbott. 
 
*Corresponding author contact information: 
Dr. Alfonso Fasano, MD, PhD 
Chair in Neuromodulation and Multi-Disciplinary Care 
This article is protected by copyright. All rights reserved.
Professor of Neurology - University of Toronto 
Clinician Investigator - Krembil Research Institute 
Movement Disorders Centre - Toronto Western Hospital 
399 Bathurst St, 7McL412, Toronto, ON Canada M5T 2S8 




Background. While the COVID-19 pandemic is affecting a relatively small proportion of the global 
population, its effects have already reached everyone. The pandemic has the potential to differentially 
disadvantage chronically ill patients, including those with Parkinson’s disease (PD). The first healthcare 
reaction has been to limit access to clinics and neurology wards to preserve fragile PD patients from 
being infected. In some regions shortage of medical staff has also forced movement disorders 
neurologists to provide care for COVID-19 patients. 
  
Objective. To share the experience of various movement disorder neurologists operating in different 
world regions and provide a common approach to patients with PD, with a focus on those already on 
advanced therapies, which may serve as guidance in the current pandemic and for emergency situations 
which we may face in the future.  
 
Conclusion. Most of us were unprepared to deal with this condition, given that in many health care 
systems telemedicine has been only marginally available or only limited to email or telephone contacts. 
In addition, to ensure sufficient access to intensive care unit beds, most elective procedures (including 
deep brain stimulation or initiation of infusion therapies) have been postponed.  
We all hope there will soon be a time when we will return to more regular hospital schedules. However, 
we should consider this crisis as an opportunity to change our approach and encourage our hospitals 
and health care systems to facilitate remote management of chronic neurological patients including 
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Introduction 
Over the past 20 years, pandemics such as severe acute respiratory syndrome coronavirus (SARS Co-V),1 
Middle Eastern respiratory syndrome (MERS),2 and influenza (H1N1 and H5N1) have placed a strain on 
the healthcare systems and societies. It’s now the turn of SARS Co-V2, which emerged in the region of 
Wuhan in China around December last year and spread so rapidly that the World Health Organization 
declared coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020. The virus shares highly 
homologous sequences with SARS Co-V and although most subjects may be asymptomatic or only 
develop mild upper respiratory symptoms, severe manifestations occur, including acute respiratory 
distress syndrome eventually resulting in death.3 
Severe neurologic complications have been associated with human coronavirus infections but to date, 
no rigorous evidence exists of direct neurologic involvement of the novel SARS Co-V2 (Suppl Table 1).4 
Most of these manifestations are unspecific and generally associated with viral infections. Anosmia and 
ageusia have been consistently described but their pathophysiology is still unclear. 
 
In this view-point-review we want to share the experience and opinion of various movement disorder 
centers operating in different world regions in order to discuss the impact of the current humanitarian 
crisis of COVID-19 on Parkinson disease (PD) patients on advanced therapy and provide a common 
approach to their care. We decided to focus on patients already on advanced therapies as they 
inherently feature a baseline frailty greater than PD on oral medications. In addition, due to the 
complexity of their treatment (i.e. device-aided and requiring parameter adjustments), they pose  
greater management challenges. In fact, with restrictions on travel being imposed and elective patient 
appointments being cancelled, there is an urgent need for alternative models of care. 
 
 
COVID-19 and Parkinson’s disease 
The COVID-19 pandemic has forced health systems to rapidly change priorities in medical care and this 
has had a dramatic impact on many patients with chronic conditions including those with PD. Certain 
preexisting medical conditions and male gender appear linked to more severe manifestations of the 
This article is protected by copyright. All rights reserved.
infection and the elderly and immunocompromised persons are particularly vulnerable. This raises three 
questions: 1. Does advanced PD pose an increased risk of morbidity and mortality in COVID-19 patients? 
2. Does SARS Co-V2 complicate the clinical course of PD? 3. How we can manage PD patients on 
advanced therapies in times of this pandemic and during future humanitarian crises will be the focus of 
the sections below. 
 
Does advanced PD pose an increased risk of morbidity and mortality in COVID-19 patients? 
Physical frailty in older adults is common and associated with a wide range of adverse health outcomes 
including mortality and higher disability.5 Frailty may occur in up to 50% or more of adults by the age of 
85.6 Accurately identifying frailty in patients with PD may have prognostic and therapeutic implications 
as has an impact on quality of life, morbidity and life expectancy.7-10 Frailty has been shown to be 
common in PD, affecting 22.2% of community-based patients.11 PD patients are nearly twice as likely to 
be admitted to hospital for complications of the disease and its treatment than for management of the 
primary motor deficit, with pneumonia being the second commonest diagnosis in most of the studies.12  
 
Little information is available on the relationship between PD and humanitarian crises. Of 631 UK 
patients hospitalized during the first pandemic wave of H1N1, neurological comorbidities failed to 
correlate with disease severity or duration of hospitalization.13 A retrospective study of 397,453 patients 
aged ≥60 years with Parkinsonism found lower in-hospital mortality than those patients without 
Parkinsonism (odds ratio= 0.81; 95% confidence interval= 0.74–0.89). However, length of stay was 8.1% 
longer in patients with Parkinsonism, who were also less likely to be discharged home (0.62; 0.58–0.67). 
Higher age, lower body mass index, lower Barthel index, higher A-DROP (Age, Dehydration, Respiratory 
Failure, Orientation Disturbance, and Blood Pressure) score, and a Charlson comorbidity index ≥3 were 
significantly associated with higher in-hospital mortality.14 In another retrospective study, mortality was 
12.5% after the ICU admission in 62 PD patients with sepsis and variable age, duration and severity of 
underlying conditions. In addition, a Hoehn and Yahr score >3 was associated with higher mortality, 
which also increased over the 18 months of follow-up, and only 38% of these patients returned home.15  
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Another source of information comes from studies exploring the effect of earthquake or war on PD 
patients, most of which described a worsening of symptoms due to the combination of stress on motor 
and mental function as well as limited healthcare resources (e.g. lack of doctors and anti-PD 
medications).16, 17 Interestingly, some of these patients presented an unexpected improvement of their 
motor function attributed to paradoxical kinesia and lasting up to 4 months.18 Given its variable 
occurrence, it has been argued that cognitive impairment often accompanies such paradoxical 
improvements.19 
 
Presently, there is insufficient evidence in the literature showing that PD by itself worsens COVID-19 
outcome.20 However, patients with advanced PD with restricted pulmonary capacity due to axial 
akinesia are at higher risk for pulmonary decompensation. In addition, it is well known that 
Parkinsonism tends to decompensate with acute stress and particularly with fever, both key symptoms 
of COVID-19.21 Under these circumstances, PD patients are at risk of developing severe generalized 
akinesia or akinetic crises, and dopaminergic medication may require a rapid increase.22 
 
Does SARS Co-V2 complicate the clinical course of PD? 
SARS Co-V1 has been detected in the CSF of a patient with encephalitis and acute respiratory distress 
syndrome.23 SARS Co-V2 has been recently reported to cause meningoencephalitis in a 24-year-old man 
and encephalopathy in a 74-year-old PD patient.24, 25 Does COVID-19-associated anosmia suggest the 
involvement of the olfactory bulbs? In mouse models of coronavirus encephalitis, the virus can enter the 
brain trans-neuronally through the olfactory pathways. Indeed, it has been argued that SARS Co-V2 
might have a direct detrimental effect on bulbar respiratory centre.26 Interestingly seropositivity for 
coronaviruses has been reported in a variety of neurological disorders, including PD.27 The significance 
of these findings is not clear. A possible increase of PD incidence in COVID-19 survivors has been 
hypothesised,21 although in many case anosmia is transient, suggesting it does not destroy olfactory 
neurons. 
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Theoretical uncertainties aside, PD patients are certainly facing increased levels of stress that may have 
several short-term as well as long-term adverse consequences (Figure 1).21 
 
The stress on healthcare systems 
The first reaction of the medical community has been to limit the access of non-urgent patients to clinics 
and wards. In some regions shortage of medical staff has forced movement disorders neurologists to 
provide care for COVID-19 patients. In an attempt to prevent fragile PD patients from being infected, 
appointments have been postponed and many have been left without the option to obtain a 
consultation. Most neurologists were unprepared to deal with this condition as in many health care 
systems telemedicine has been only marginally available or only limited to email or telephone contacts. 
In addition, to ensure sufficient access to Intensive Care Unit (ICU) beds, most elective surgical 
procedures have been delayed including deep brain stimulation (DBS). The initiation of infusion 
therapies such as levodopa-intestinal gel (LCIG) or apomorphine have also been postponed as they are 
classified as “non-urgent”. Furthermore, many patients have deliberately chosen to skip appointments 
due to the fear of being exposed to the risk of the contagion.28 
A particular challenge may be the emergency admission of patients living in nursing homes. For fear of 
in-house outbreaks local authorities or nursing homes have instituted strict quarantine regulations for 
external admissions and it may be difficult to discharge a patient back into institutional care after 
successful treatment. In these cases social services need to prepare relatives and mobile nurse services 
for the extra burden of home care. 
 
Management of Advanced Therapies 
Regardless of the device-aided treatment in place, the first step is an accurate triaging of patients in the 
current scenario. Figure 2 depicts the general approach to this process. At Toronto Western Hospital 
25% of visits have been postponed, 70% converted into telemedicine visits and 5% kept as originally 
planned as in-hospital visits. Reassurance should be given to patients that emergency care will remain 
accessible if absolutely necessary and the health care provider should make sure the patients or carers 
have all the necessary phone numbers. 
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In addition, the manufacturer´s product specialists are available to be contacted by phone or – in 
selected cases and depending on the geography – they can also provide home visits on a regular basis or 
when needed, although this may be difficult during lockdown. Manufacturers can also ship pieces of 
equipment, e.g. to replace malfunctioning pumps or patient controllers.   
 
The following sections will discuss in more details the approach depending on the type of advanced 
therapy. 
 
Levodopa/Carbidopa Intestinal Gel Continuous Infusion 
More than 12000 PD patients are treated worldwide with LCIG. A similar intestinal gel containing 
levodopa, carbidopa plus entacapone was recently launched in Scandinavia, Levodopa-Entacapone-
Carbidopa Intestinal Gel (LECIG).29, 30 The gel is delivered continuously by a portable pump via a catheter 
through a percutaneous endoscopic gastrostomy (PEG) to the upper part of the small intestine. The 
treatment is normally given as daytime treatment but can, if needed, be given over 24 hours.31 Adverse 
events most commonly relate to the PEG surgery and/or the infusion device and include infections and 
rarely peritonitis. The majority of adverse events occur during the first weeks after the PEG 
implantation.29 
 
Does the use of LCIG increase patient’s risks during a pandemic/other crises? 
There is no case report or even theoretical reason to believe that LCIG/LECIG therapy would increase 
risks during an infection or other crisis. To the contrary, since LCIG/LECIG treatment improves motor 
status and many non-motor aspects, it could theoretically improve the patients’ capacity to deal with an 
infection by diminishing off-period duration. Nevertheless, initiations of new patients on LCIG should be 
postponed during a public health crisis such as a pandemic. 
 
Care of systemic issues (infections, organ failures) in LCIG patients 
There are no indications that LCIG/LECIG treatment would be a disadvantage compared with oral 
treatment when patients have other severe illnesses, e.g. a severe infection and/or organ failure. 
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Care of LCIG patients in times of humanitarian crisis 
It is convenient for healthcare centres to establish routines for video consultation (see below). Apart 
from the consultation, it can also be valuable to get objective and quantitative monitoring of the 
patients’ status,32, 33 for example monitoring the status of the PEG (Figure 3A). The programming of the 
pump and thereby the dosing of LCIG/LECIG can mostly be handled by the patient/caregiver after 
instructions from the doctor/nurse over telephone/video. The pump can be kept in a non-locked mode 
to make this process easier, although this should be weighed against certain risks, as in patients with a 
history of dopa dysregulation syndrome.  
A delivery service for the transport of LCIG/LECIG from the pharmacy to the patient is beneficial. 
However, patients should always have instructions for emergency oral levodopa therapy and storage of 
enough quantity (Table 1).  
 
Strategy in case of sudden failure/withdrawal of the therapy 
In case of LCIG/LECIG delivery difficulties or pump failure, most countries have an emergency telephone 
number, where the patient/caregiver can get advice on how to solve the problem or get a quick delivery. 
In the meantime, patients shall use their oral emergency medication (Table 1).  
In case of blockage in the catheter, the patient/caregiver should have a checklist with steps that they 
can take themselves. If this does not help, contact with the hospital is necessary and the patient has to  
immediately switch to his/her oral emergency medication prescription. If there is a suspicion that the 
catheter has been displaced to the stomach (resulting in an irregular effect of the medication), the 
patient can continue the pump treatment and repositioning of the catheter to the jejunum can be 
performed later. 
 
Subcutaneous Apomorphine Continuous Infusion 
Apomorphine is a highly efficacious dopamine agonist administered subcutaneously, either as 
intermittent injections or as a continuous infusion using various externally worn mini-pump systems.34 
Apomorphine typically replaces some or even all of a patient´s oral medication during the daytime and 
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24-hour use is possible. Adverse effects include skin changes, nausea, somnolence, neuropsychiatric 
issues, orthostatic hypotension, ankle edema and, rarely, drug-induced immune hemolytic anemia or 
eosinophilia.35, 36 
The frequency and type of routine follow-up and clinic visits varies among health care systems.37, 38 
Routine blood checks are typically done every 3-12 months, however no interval can be defined that 
would guarantee early detection of hematologic issues. Therefore, centres typically provide information 
to the patients and carers on the symptoms of possible anemia. 
 
Does the use of apomorphine increase patient’s risks during a pandemic/other crises? 
The full clinical spectrum of COVID-19 is not yet known but to date, there is no suggestion of features 
that would directly interfere with the use of apomorphine. Initiations of new patients on apomorphine 
should be postponed during a public health crisis such as a pandemic. However, among the device-aided 
therapies apomorphine infusion remains the easiest to implement. 
 
Care of systemic issues (infections, organ failures) in apomorphine patients 
If PD patients using an apomorphine infusion require in-patient or ICU admission because of COVID, 
continued use of apomorphine – as with LCIG – is generally recommended if possible to avoid motor 
worsening. Specific training is required to manage the pump system, but apomorphine can be switched 
to a regular infusion system which delivers the usual hourly flow rate into the subcutaneous tissue, 
usually during daytime only. In patients who have used 24-hour apomorphine before entering the ICU, 
this should be maintained if possible (see below). If apomorphine vials are not available or the acuity of 
the situation does not allow setting up an extra infusion system, oral levodopa should be used (Table 1). 
 
Care of apomorphine pump patients in times of humanitarian crisis 
Routine laboratory tests should be postponed. Sending pictures of skin changes may be sufficient and 
may avoid personal visits. As with LCIG, leaving pumps unlocked should be considered (except if there is 
a risk of dopaminergic dysregulation). During prolonged crises and under certain circumstances, it may 
be possible to guide a patient or carer through the steps of unlocking the pump and changing the flow 
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rate remotely, although persons with impaired manual dexterity, cognitive issues or lack of experience 
with technical devices in general will find this difficult. Clinicians should make the judgement whether 
this can be done safely, particularly when the alternative would be to discontinue the infusion, which 
would also pose risks that would be difficult the manage remotely. Pre-set various flow rates for 
different times of the day, or for daytime and nighttime, is also a useful tool to consider. However, 
during a public health crisis any changes should only be made if deemed necessary because of the 
reduced capacity to respond to the potentially resulting deterioration in the patients´ state.  
 
Strategy in case of sudden failure/withdrawal of the therapy 
As with levodopa, sudden withdrawal of apomorphine infusion typically leads to marked motor 
worsening including malignant akinesia, particularly if it has provided a large proportion or all of a 
patient´s dopaminergic treatment. Dopamine agonist withdrawal syndrome, including acute lethargy, 
may also occur.39 Therefore, centres that initiate patients on apomorphine infusion should provide 
recommendations on how to proceed in case of pump failure or withdrawal of apomorphine for any 
reason. The typical recommendation is the return to the patient´s oral medication prior to pump use, 
plus additional oral levodopa as required until the issue can be fixed. However, this may no longer be 
the best choice in patients who have used apomorphine for many years and where the illness itself has 
progressed. In these patients, levodopa monotherapy may be more appropriate (Table 1). Patients or 
carers should be reminded that a larger than usual supply of oral replacement medication should be 
obtained and kept at home. 
 
Deep Brain Stimulation 
Subthalamic nucleus (STN) and globus pallidus pars interna (GPi) stimulation can improve motor 
complications and cardinal signs of the disease while ventral intermediate nucleus of the thalamus 
stimulation only improves tremor.40 People with implanted DBS systems have additional distinct specific 
needs. For example, the implantable pulse generator (IPG) can be rechargeable or function as ‘primary 
cells’: the former can last between 10 and 25 years whereas the latter require replacements every 3-5 
years.41 
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Does the use of DBS increase patient’s risks during a pandemic/other crises? 
There is no suggestion that a viral respiratory infection would directly interfere with the use of DBS. 
However the majority of clinicians confronted with a DBS patient will not be comfortable with the 
methods of programming of the DBS and checking its normal functioning, nor will they be confident 
whether the DBS itself poses additional risks/challenges in the context of potentially changing 
healthcare needs, e.g. cardiac monitoring (see below). Commonly, changes in PD symptom severity may 
be attributed to the DBS by the unwary, while in reality these often result from common problems such 
as infections, constipation or metabolic upset. 
 
Care of systemic issues (infections, organ failures) in DBS patients 
If PD patients on DBS therapy require in-patient or ICU admission, continued use of DBS is 
recommended because of the major worsening of motor function as well as onset of painful 
rigidity/dystonia that can accompany prolonged withdrawal of DBS. In addition, DBS also provides PD 
treatment when dopaminergic drug delivery cannot be guaranteed. This is particularly relevant to STN 
DBS as it allows a greater medication reduction than GPi DBS.40 A possible limitation introduced by DBS 
is the electric artifact on EEG or ECG traces.42 This can be managed either by turning the DBS off for few 
minutes during the ECG/EEG acquisition (easily possible by using the patient’s own controller) or – 
whenever not possible (e.g. severe tremor, prolonged monitoring) – by using a bipolar DBS 
configuration, i.e. both anode and cathode are on the lead, thus resulting in a narrow electrical field 
around the electrode (this requires input from the DBS specialist team).41 
 
Care of DBS patients in times of humanitarian crisis 
Familiarity with the common problems associated with DBS, allows experienced clinicians to spot when 
a new set of symptoms requires detailed investigation or those occasions when it may be more likely 
amenable to minor DBS adjustments. These types of issues can be readily detected through telephone 
or video consultation but nevertheless require clinicians that are confident and experienced in dealing 
with DBS. It is therefore vital that all DBS patients have access to specialist advice whenever necessary. 
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All the modern DBS platforms allow patients to adjust their DBS parameters within pre-arranged 
windows by means of controllers that can access the implanted hardware with telemetry. Patients 
should be educated how to use their own patient controllers to allow fine tuning of settings as well as 
performing battery checks on a regular basis. In the absence of face-to-face consultations, video 
consultations can greatly facilitate checking and verifying that settings and battery life are as they 
should be, or to help remotely instruct patients how to make minor DBS adjustments (Figure 3B).  
Options for alternative stimulation programs can also be pre-programmed into modern IPGs. Alternative 
stimulation settings may be made available in anticipation of future eventualities and permitted for 
patients with sufficient technical competence.43 However, it is not usually possible to anticipate and pre-
emptively make settings available in the long term with the range of possible changes in symptoms that 
may occur as a result of disease progression. Sudden failure of symptom control especially in the context 
of falls/head injury, or signs of local DBS infection typically need urgent face-to-face consultation to 
interrogate the normal functioning of the hardware and any further investigations/neurosurgical input. 
For some of these scenarios it is however possible to screen the condition with telemedicine (Figure 3C). 
The most common source of sudden withdrawal of the therapy is end of battery life, which must be 
avoided by ensuring that the battery level is appropriately checked by either the patient or a clinician on 
a regular basis.  
 
Strategy in case of sudden failure/withdrawal of the therapy 
It must be clearly communicated that, particularly in case of STN stimulation, sudden DBS failure can 
constitute a medical emergency caused by a life-threatening akinetic crisis similar to a neuroleptic 
malignant syndrome (‘malignant STN DBS withdrawal syndrome’).44 Timely replacements should be 
continued even during times of crisis/emergency to prevent more substantial emergency care being 
subsequently required, although different scenarios and prioritization of patients should be kept in mind 
(Table 2). High doses of levodopa can be established in these cases but response might be poor after 
many years on lower doses. 
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A framework for better care 
PD patients treated with advanced therapies typically show high symptom variability that requires 
frequent monitoring. With the COVID pandemic, PD experts have rapidly found themselves operating in 
an evidence-free zone where the virus’ mitigation measures have created an urgent need to check in on 
advanced therapy PD patients’ welfare.  
 
Telemedicine 
The validity of telemedicine to assess PD patients has been well documented in many studies (for a 
review see45). Telemedicine is the use of electronic information and communication technology to 
provide and support healthcare when distance separates participants. It is traditionally subdivided into 
synchronous (interactive video connection) and asynchronous telemedicine (store-and-forward 
transmission of medical images and/or data).46 The epidemic has already driven rapid innovation and 
implementation of these systems for the delivery of urgent and ongoing health care. A major benefit of 
expanding telehealth with no restrictions would reduce person-to-person contact between health 
service providers and COVID-19 and reduce the risk of exposure of noninfected but susceptible patients 
in waiting room areas. The Telemedicine Study Group of the International Parkinson and Movement 
Disorders Society has recently updated a guide to telemedicine to reflect these recent changes.47 
 
Simple communication methods such as e-mail and text messaging should be used more extensively to 
provide general support,48 especially as a suitable modality for lower-income regions or for areas lacking 
the bandwidth and continuous connectivity to perform synchronous telemedicine.46 Another benefit of 
asynchronous telemedicine is that videos can be obtained for patients experiencing paroxysmal 
movement disorders. Nevertheless, for many people with PD video-conferencing is widely accessible 
and can provide clinicians with useful motor and nonmotor assessments of patients symptoms,49, 50 also 
approved of by patients.51 Video assessments of parkinsonian symptoms or dyskinesias are helpful. In 
most cases, the advice given during telemedicine sessions will refer to simple strategies, such as 
changing the dosages of oral medications or the duration of pump use. 
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Important limitations of video conferencing are acknowledged, yet a modified version of the motor 
UPDRS without rigidity and retropulsion pull testing is reliable as well as guidelines for filming gait and 
movement disorders.52, 53 The feasibility of conducting the Montreal Cognitive Assessment remotely in 
patients with movement disorders has also been proved.54 
 
Ambulatory movement measurement devices can be mailed out to patients prior to telehealth 
appointments. Results can be readily available prior to the appointment and provide a longitudinal 
assessment in an ecologically valid setting. These devices have been suggested to provide useful 
additional information to assess the DBS effect.55 A portable monitoring system is also possible although 
the elements necessary for the remote assessment still require formal testing.56 
 
Remote programming 
The current pandemic highlights the urgent need for further innovation in particular around remote 
access to device programming. Hopefully, implementation of remote programming capabilities will 
progress before the results of pilot studies reported hitherto.57-59 Telemedicine has been used in one 
small open-label study to assist with LCIG titration where it was found to be more resource-efficient, 
technically feasible, well-accepted and satisfactory to patients, neurologists, and nurses than hospital-
based management.58 Although pilot studies have been performed,57 to our knowledge, no pump 
system is currently in clinical use that would allow for remote programming of apomorphine infusion 
settings. 
 
Canada is home to one of the most established telemedicine programs: the Ontario Telemedicine 
Network (OTN), which is being operated through a secure Internet-based system since 2001. OTN 
provided telehealth services to 785,986 patients, over 1200 patients with movement disorders in 2017, 
and continues to provide care for advanced PD patients, including those with DBS.59 Jitkritsadakul et al. 
analyzed the possibility of an ‘indirect’ intervention on DBS parameters, supervised by an expert 
physician through OTN and physically enacted directly by the patient or caregiver by means of the 
patient’s controller.59 The number of video-guided visits directly correlated to the distance between 
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home and the DBS referral center, allowing a significant reduction in the logistical burden associated 
with travel time and costs. The volume of these visits has increased since the beginning of pandemic, 
also using less conventional systems such as Zoom or Skype (Figure 2B) (Suppl Table 2). This is the result 
of the lifted restrictions on sensitive data/privacy (e.g. HIPPAA) to contrast this unprecedented request 
of healthcare access, although there is a country-specific regulatory landscape.60 
 
DBS stimulation parameters and infusion systems parameters could theoretically be modified directly 
from a remote location via a Bluetooth-based programming system installed at the patient’s home. PINS 
Medical (Beijing, China) and SceneRay Corporation Ltd. (Suzhou, China) are two DBS manufacturers 
promoting web-based, remote, wireless DBS programming systems, in which patients may have their 
DBS settings adjusted at home by a clinician remotely located in a hospital or clinic.61-63 These systems 
are only available in China and it is unclear if they will ever reach the global market. Abbott systems, on 
the other hand, also features a locked capability for web-based remote programming, which is currently 
under investigation. A 6-month pilot study on 32 PD patients enrolled in a prospective, double-blind 
study, is currently undergoing in Australia. Patients are randomly assigned to remote care paradigm or 
standard of care protocol. For the first session, all subjects are connected to an experienced 
programmer remotely via a mobile platform while being in a clinic room with another expert 
programmer. A third blinded assessor determines programming effectiveness acutely (20 mins post 
session) and over time (3 weeks post first follow-up programming session). The primary endpoint is to 
evaluate the safety of the remote care paradigm. Secondary endpoint is the difference in UPDRS-III 
scores between first follow-up programming and 3-week assessment.64 
 
Other roles of telemedicine 
Telerehabilitation – also including speech therapy, a common problem in DBS and advanced cases – is 
possible as well as telepsychiatry, which was recently tested in a cohort including many DBS patients.65 
Education of healthcare providers in the community (e.g. general neurologists) and patients is also very 
valuable. Webinars and informative websites issued by hospitals and patient organizations around the 
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globe are already heavily implemented.21 These same platforms can be used for online singing, exercise 
or dancing classes for PD patients. 
 
PD in the ICU 
There are no guidelines detailing the care strategy for PD patients admitted in the ICU,66 particularly 
with respect to the COVID-19 pandemic. As detailed before, efforts should be put in place to guarantee 
anti-PD therapy although the severity of clinical manifestations may require changes in therapeutic 
regimen. In case of pneumonia, physicians must ensure the maintenance of previous PD medications (or 
an adequate levodopa equivalent dose) to avoid rigidity with contractures and respiratory impairment 
with reduced vital capacity and peak expiratory flow.22  
In a severely akinetic patient with dysphagia, the easiest, cheapest and most efficient way of rapidly 
adapting PD therapy is by means of highly fractionated doses of levodopa solution infused with a 
nasogastric tube, typically administrated at 2-3 hour intervals day and night. However, COVID-19 causes 
not only severe interstitial pneumonia but determines diffuse thrombosis secondary to direct viral 
diffuse endothelial damage.67 Most subjects need to initiate anticoagulant therapy beside invasive 
mechanical ventilation which is in some cases continued for weeks. Therefore, while in principle 
administration of levodopa through a nasogastric tube is advisable, it may not be practical given the 
enormous pressure on physicians and nurses working on COVID-19 ICU. 
Apomorphine pump therapy and LCIG could be continued if already implemented (see above). Using 
apomorphine when oral administration of any drugs is not possible has been recommended even in PD 
patients without prior exposure to apomorphine, e.g. perioperatively,68 although in the setting of an 
acute COVID-19 ICU this approach can only be considered if malignant akinesia poses a real risk to the 
patient. 
 
The only other broadly available non-oral antiparkinsonian drug is transdermal rotigotine but it is 
considerably less efficacious than levodopa or apomorphine and can be considered as a minimal 
bridging measure to avoid severe withdrawal symptoms. Similarly, intravenous amantadine is 
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commercially available in some countries but it is also much less efficacious and carries risks including 
QTc prolongation and agitation that should be kept in mind. 
 
Conclusions 
In the recent past there have been many major epidemics. This includes Ebola, Zika, Dengue, 
Chikungunya, acute flaccid myelitis and H1N1 influenza, to name a few. Yet telehealth has received a 
push back in many healthcare systems, for the past 10 years in the USA for example, and in the EU due 
to data protection concerns. There are still many regulatory unknowns, such as medical license issues 
for patients seen from out of province/country or liability and billing uncertainties. In any case, an 
effective uptake of telemedicine strategies at this time will likely minimize the impact on physical and 
mental health in this vulnerable population of patients - both on a short- and long-term basis.  
The COVID-19 pandemic is an opportunity to change our approach to chronic neurological patients, 
including those with advanced PD, particularly encouraging our hospitals to facilitate the use of tools for 
remote management and companies to develop an easy, validated and reliable remote access control of 
IPGs and continuous delivery pumps. The medical community should promote initiatives to evolve and 
standardize the kinematic measurement of motor function, including rigidity and gait. In conclusion, the 
COVID-19 pandemic is teaching us many lessons, such as the pivotal role of levodopa in case of system 
failure for any advanced therapy or the effect of social distancing and lockdown measures on frail 
patients with PD. In fact, this crisis also calls for the rapid introduction of better self-management 
strategies that can help patients to better deal with the challenges of social distancing and the other 
consequences of this crisis. 
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Table 1. Current Practical conversion scheme from pump-based therapies to oral levodopa (based on69) 
 
LCIG → oral levodopa* 
Morning dose (ml x 20mg/ml - 3ml) + 
Continuous dose (ml/h x 20mg/ml x hours of infusion) + 
Extra dose (ml x 20mg/ml x average number of extra doses/day) = 
Total levodopa dose that should be substituted per day 
LECIG → oral levodopa* 
Morning dose (ml x 20mg/ml x 1.3 - 3ml) + 
Continuous dose (ml/h x 20mg/ml x 1.3 x hours of infusion) + 
Extra dose (ml x 20mg/ml x 1.3 x average number of extra doses/day) = 
Total levodopa dose that should be substituted per day 
Apomorphine → oral levodopa* 
Continuous dose (mg of apomorphine/h x hours of infusion) x 10 =  
Total levodopa dose that should be substituted per day 
Abbreviations: * = levodopa solution for nasogastric tube in akinetic crises can be prepared diluting 1000 
mg of crushed levodopa (dispersible formulation if available) into 1000 ml of water and adding 1 gr of 
Vitamin C (plus domperidone in case of delayed gastric), LECIG = Levodopa Entacapone Carbidopa 
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Table 2. Current recommendations in place at Toronto Western Hospital for IPG replacement during the 
COVID-19 pandemic. 
 
Recommendations for DBS patients with batteries close to end of service: 
1. Alert the team and neurosurgeon’s office 
2. Flag high risk patients (e.g. severe dystonia in the off state, brittle PD or risk of NMS-like 
picture) 
3. Patients should be informed that some decline of symptoms is possible, more and more as 
the voltage drops 
4. Ask patient to monitor their controller, depending on the manufacturer: 
• Abbott/St Jude Medical (Chicago, IL, USA):  
• With 3 months or more notice for most patients, patient controller will 
display “Replace Generator Soon” followed by self-explanatory text 
advising the patient to contact the treating physician. 
• If the patient inadvertently dismisses the alert, generator status can be 
checked by the patient (if required) with instructions from the clinician, 
qualified representative or Technical helpline. 
• In the ERI period the generator status indicator on the patient controller 
displays a yellow triangle with an exclamation sign. 
• Boston Scientific (Valencia, CA, USA):  
• When IPG is nearing end of battery life, it will enter the elective 
replacement mode, i.e. stimulation continues and the remote still has some 
functionality but additional programming with the Clinician Programmer 
cannot occur. 
• Controller will alert patient displaying “ERI” (elective replacement indicator) 
on the screen. 
• Patients on at least 12 months of DBS will have a minimum of 4 weeks 
before reaching the EOS. 
• Medtronic (Dublin, Ireland): 
• Patient controller will alert patient displaying “ERI” (elective replacement 
indicator) on the screen when cell voltage is below 2.60V. 
• Patients will only see ERI on their remote but pressing any button they will 
be able to see the normal screen and interrogate the actual battery value 
• Ask patient to monitor cell voltage every 3 to 7 days, depending on energy 
usage 
• EOS is reached at 2.20V 
Recommendations for DBS patients with IPG at end of life 
 
1. DBS is off and remote control cannot communicate with the IPG any longer.  
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• initially it might be indicated, i.e. “Replace Generator” for Abbott and “EOS” (end of 
service) for Boston Scientific and Medtronic devices. 
2. Patients should not come to the ER but let the team know so we that the best option can be 
planned.  
3. Most patients will eventually undergo the replacement of the IPG but – if absolutely 
impossible, a possible strategy would be to gradually reduce stimulation amplitude, and 
gradually compensate by increasing levodopa in order to avoid an acute cessation when end 
of IPG life is reached. 
4. Other patients might only experience a mild to moderate decline of their conditions when the 
IPG is no longer working; in these cases some adjustments (e.g. more levodopa) can be 
possible to avoid an IPG replacement on an urgent basis 
5. In case of life-threatening worsening of the condition, team should be informed and a request 
for an urgent IPG replacement should be sent. 
6. Some additional precautions might be implemented (e.g. blood work and infective screening 
before admission) 
 
Abbreviations: DBS = deep brain stimulation, EOS = end of service, ERI = elective replacement indicator, 
IPG = implantable pulse generator, NMS: neuroleptic malignant syndrome, PD: Parkinson’s disease. 
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Figures Legends 
Figure 1. The impact of SARS CoV-2 pandemic and Parkinson’s disease on patients (modified from20, 21). 
Abbreviations: BoNT = botulinum neurotoxin. SARS CoV-2 = severe acute respiratory syndrome 
coronavirus 2. 
 
Figure 2. Proposed triaging system for PD outpatients during the SARS CoV-2 pandemic. Abbreviations:  
* = after having ruled out accidental switching off or kinking/compression of the tubing system (in case 
of CSAI or LCIG), CSAI = continuous subcutaneous apomorphine infusion, DBS = deep brain stimulation, 
IPG = implantable pulse generator, LCIG = levodopa-carbidopa intestinal gel, PD = Parkinson’s disease, 
PEG = percutaneous endoscopic gastrostomy, SARS CoV-2 = severe acute respiratory syndrome 
coronavirus 2. 
 
Figure 3. Examples of telemedicine assessment in a LCIG patient showing the status of PEG (A), DBS 
patient changing stimulating parameters on her controller to improve gait (B) and a patient recently 
operated with DBS to assess the status of the surgical wounds. Abbreviations: DBS = deep brain 
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